MEDX vs SNY

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MEDX as a result. In 52 of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for MEDX just turned positive on October 12, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in 26 of 32 cases over the following month. The odds of a continued upward trend are 81%.

MEDX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 162 of 189 cases where MEDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The 10-day RSI Indicator for MEDX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 54 cases where MEDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

MEDX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 55 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 22 of 46 cases over the following month. The odds of a continued upward trend are 48%.

The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).